The event was the inaugural Edward L. Paul Lecture on Industrial Chemical Engineering
More than 40 industrial visitors, Chemical Engineering advisory board members, and friends of UVA Chemical Engineering joined faculty and students recently for the inaugural Edward L. Paul Lecture on Industrial Chemical Engineering. The lecture, given by Ed Paul himself, focused on the process development needed to bring to market a medication called CRIXIVAN(R), among the earliest of a class of HIV/AIDS anti-viral drugs that received approval from the Food and Drug Administration to combat the deadly disease beginning in the mid-1990s.
During the lecture, Paul, who graduated from UVA with a bachelor’s degree in Chemical Engineering in 1952, reflected on his time as a student and discussed key challenges related to preparing products for mass industrial production. After leaving UVA, Paul received his master’s from Princeton and his Ph.D. from New York University. He worked for 40 years at Merck biopharmaceutical company, retiring in 1994 from his position as executive director of chemical engineering research and development.
The Edward L. Paul Lecture on Industrial Chemical Engineering has been endowed thanks to the generous contributions of more than 12 individual and three corporate donors, and the endowment will support one or two industrially focused chemical engineering seminars annually.